NXPL · NextPlat Corp
The latest filing states the doubt was alleviated.
“The Company has incurred recurring operating losses and historically generated negative operating cash flows. These conditions raised substantial doubt about the Company's ability to continue as a going concern for the twelve months following the issuance of these Condensed Consolidated Financial Statements. ... Based on these results, management's projections of operating results and cash flows for the twelve months following issuance, and the Company's liquidity position, management has concluded that its plans, which are probable of being effectively implemented and probable of mitigating the relevant conditions, alleviate the substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Apr 13, 2026; bars on opposite sides are not compared.
The closing range begins at the captured split on Apr 13, 2026.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Contracted pharmacy revenue | $2.2M | second quarter ended June 30, 2026 | — |
| e-Commerce Operations gross margin | 27% | second quarter of 2026 | — |
| E-Commerce revenue | $4.1M | second quarter ended June 30, 2026 | -0.5% |
|
|
|||
| Government and military sector sales | $1.75M | through the end of the second quarter of 2026 | — |
| Healthcare Operations segment gross margin | 46% | second quarter of 2026 | — |
| Overall gross margin | 40% | second quarter ended June 30, 2026 | — |
| Total pharmacy prescription revenue | $5.6M | second quarter ended June 30, 2026 | -31.5% |
|
|
|||
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Software - Application — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NXPL
this stock
NextPlat Corp
|
$25.12M | — | +2.5% | — | 0.2% |
|
SAP
Sap SE
|
$255.70B | -8.8% | — | — | 0.7% |
|
CRM
Salesforce, Inc.
|
$210.69B | -3.4% | +25.9% | 23.4 | 3.2% |
|
SHOP
Shopify Inc.
|
$196.73B | -5.0% | +30.1% | 102.6 | 1.2% |
|
UBER
Uber Technologies, Inc
|
$160.99B | -3.5% | +18.3% | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Apr 13, 2026; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NXPL | +1.2% | +53.1% | — | +53.1% | — |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | +0.7% | +50.1% | — | +50.1% | — |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.